603739 Qingdao Vland Biotech INC.
- 13.87
- +1.26+9.99%
Qingdao Vland Biotech INC. News
Weilan Biotech (603739.SH) released 2023 results, with net profit of 80.7069 million yuan, an increase of 15.56% over the previous year
According to the Zhitong Finance App, Weilan Biotech (603739.SH) released its 2023 annual report, achieving revenue of 1,199 billion yuan, an increase of 3.07% over the previous year. Net profit attributable to shareholders of listed companies was RMB 807.069 million, an increase of 15.56% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 42.1788 million yuan, an increase of 6.21% over the previous year. It is proposed to distribute a cash dividend of 1.00 yuan (tax included) for every 10 shares to all shareholders.
Qingdao Vland Biotech (SHSE:603739) Stock Falls 18% in Past Week as Five-year Earnings and Shareholder Returns Continue Downward Trend
Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly. To wit, the Qingdao Vland Biotech INC. (SHSE:603739) share price managed to fall 60
Blue Bio (603739.SH): No weight loss related probiotics
Gelonghui, Feb. 19: Weilan Biotech (603739.SH) said on the investor interactive platform that up to now, the company has no probiotics related to weight loss.
Qingdao Vland Biotech INC.'s (SHSE:603739) P/E Is On The Mark
Qingdao Vland Biotech INC.'s (SHSE:603739) price-to-earnings (or "P/E") ratio of 41.2x might make it look like a sell right now compared to the market in China, where around half of the companies hav
Blue Bio (603739.SH): Obtained a new veterinary drug registration certificate
On January 19, Ge Longhui (603739.SH) announced that according to the “Veterinary Drug Administration Regulations” and the “Veterinary Drug Registration Measures”, after review by the Ministry of Agriculture and Rural Affairs, it was approved by Qingdao Weilan Biology Co., Ltd. and its wholly-owned subsidiaries Qingdao Health Insurance National Engineering Technology Research Center Co., Ltd. and Qingdao Kangdian Animal Pharmaceutical Co., Ltd. as three new veterinary drugs, and recently announced the issuance of the “New Veterinary Drug Registration Certificate”.
Weilan Biotech (603739.SH): Wholly-owned subsidiary obtains a new veterinary drug registration certificate
On January 2, Gelonghui Biotech (603739.SH) announced that after review by the Ministry of Agriculture and Rural Affairs, it approved the “Little Goose Fever Freeze-dried Egg Yolk Antibody” jointly declared by Qingdao Weilan Animal Health Group Co., Ltd., a wholly-owned subsidiary of Qingdao Weilan Biology Co., Ltd. and other organizations, as three new types of new veterinary drugs, and recently announced the issuance of the “New Veterinary Drug Registration Certificate”.
These 4 Measures Indicate That Qingdao Vland Biotech (SHSE:603739) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Blue Biotech (603739.SH): The synthetic biotechnology innovation laboratory disclosed earlier is mainly used to develop functional proteins, sweeteners, etc.
On December 26, Gelonghui (603739.SH) announced an announcement of abnormal fluctuations in stock trading. Recently, the company noticed that the Internet and some media published reports on “synthetic biology”. The company's main business is R&D, production and sales of enzyme preparations, microecological preparations, and animal health products. According to the company's 2022 annual report, revenue from enzyme preparations was 421.684 million yuan, accounting for 37.16% of main business revenue; revenue from microecological products was 251.0956 million yuan, accounting for 22.13% of main business revenue; revenue from animal health products was 299.963 million yuan
Blue Biotech (603739.SH): Plans to suspend construction of microecological formulation research and industrialization projects
Gelonghui (603739.SH) announced on November 2, that due to the cyclical nature of project construction and operation, according to the business development plans of the two parties, after careful analysis, Azure Biotech Group and ADM Singapore signed the “Supplement Agreement 2 to the Revised Shareholder Agreement” and the “Shareholders' Meeting Resolution” on November 2, 2023. The two sides intend to suspend the construction of microecological formulation research and industrialization projects, and will adjust the joint venture's business plan according to the actual situation. Other cooperation projects between Azure Biotech and ADM are progressing smoothly. Construction of the project has been suspended and joint venture plans are planned
Net profit of 55.32 million yuan for the first three quarters of the year released by 603739.SH increased 2.05% year-on-year
Azure Biotech (603739.SH) disclosed its report for the third quarter of 2023. The company achieved operating income during the reporting period...
Qingdao Vland Biotech Forms Chinese JV With Germany's Evonik
Qingdao Vland Biotech (SHA:603739) has agreed to establish a Chinese joint venture with Germany's Evonik Industries through its Chinese arm, Evonik (China) Investment. Vland subsidiary Shandong Weilan
Azure Biotech (603739.SH) plans to establish a joint venture to deepen business cooperation with German Evonik Group (EVONIK)
Weilan Biotech (603739.SH) announced that Shandong Weilan Biotechnology Co., Ltd., a wholly-owned subsidiary of the company (“Shandong...
Weilan Biotech (603739.SH): Subsidiary Shandong Weilan plans to invest 16.875 million yuan to participate in the joint venture to exclusively produce GHS products for the joint venture through OEM processing
Glonghui, Oct. 12, 丨 Blue Biotech (603739.SH) announced that Shandong Weilan Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, and Evonik (China) Investment Co., Ltd. signed a “Shareholder Agreement” on October 12, 2023. The two sides plan to jointly establish a Sino-foreign joint venture (hereinafter referred to as the “Joint Venture”) in Huimin County, Binzhou City, Shandong Province, China. Shandong Weilan Biotechnology Co., Ltd. will accept the commission of the joint venture to exclusively produce GHS products for the joint venture through OEM processing. Shandong Weilan and Evonik China will conduct business related to GHS products in accordance with the Shareholders' Agreement
Weilan Biotech (603739.SH): The completion and acceptance of the company's new animal insurance base has been completed
Glonghui, Oct. 12 | An investor asked Blue Bio (603739.SH) on the investor interactive platform, “How is the utilization rate of the company's mobile insurance base and whether it is growing steadily?” The company said that the completion and acceptance work of the company's new mobile insurance base has been completed and is currently gradually being put into production and operation.
Azure Biology (603739.SH): Received a government grant of RMB 1,8712 million
Glonghui, Oct. 9, 丨 Blue Biotech (603739.SH) announced that from May 2023 to October 2023, the company and its subsidiaries have received a total of RMB 128.712 million in government grants related to revenue, accounting for 18.43% of the company's audited net profit for the most recent fiscal year.
Azure Biology (603739.SH): Targeted development of functional complex microecological products for aquaculture
Glonghui, September 14: Azure Biology (603739.SH) stated on the investor interactive platform that the company is developing fisheries-specific functional composite microecological products in a targeted manner in the direction of aquaculture microecology, with the aim of helping aquaculture and serving aquaculture, improving the external environment of aquaculture and conditioning the internal environment of farmed animals. Among them, in terms of water quality improvement, a series of functional products that solve different water quality problems at the aquaculture side have been developed, which can effectively decompose organic matter and harmful substances such as ammonia nitrogen and nitrite in aquaculture water, and regulate water quality indicators such as pH in aquaculture water; in terms of biological prevention and control, specific products targeting different pathogens have been developed
Blue Biotech (603739.SH) released semi-annual results, net profit of 31.47 million yuan, down 15.87% year on year
According to Zhitong Financial App, Blue Biotech (603739.SH) disclosed the 2023 semi-annual report. During the reporting period, the company achieved revenue of 544 million yuan, an increase of 2.13%; net profit of 31.47 million yuan, a year-on-year decrease of 15.87%; net profit of 17.27 million yuan, a year-on-year decrease of 28.65%; and basic earnings per share of 0.12 yuan. In the first half of 2023, 32 domestic authorized invention patents were added, and 3 PCT international applications were filed. By the end of the reporting period, the company and its subsidiaries had 367 domestic authorized invention patents, 8 US authorized patents, and 2 European authorized patents
Qingdao Vland Biotech Acquires 51% of Runbot Biotechnology for 91.8 Million Yuan
Qingdao Vland Biotech (SHA:603739) acquired 51% of Qingdao Runbot Biotechnology for 91.8 million yuan. The Chinese biotechnology products manufacturer will acquire the equity from third-party investor
Blue Biotech (603739.SH): Plans to acquire 51% of Runbot's shares for RMB 91.8 million
On July 20, | Blue Biotech (603739.SH) announced that according to the company's strategic development needs, in order to further enrich the company's product structure and improve the animal health system, the company plans to acquire Qin Wei, Qin Qilong, Zhang Xiaodong, Chen Qiang, Qingdao Jurun Management Consulting Partnership (Limited Partnership) and Qingdao Gerupu Management Consulting Partnership (Limited Partnership) with a total of 51% of the shares of Qingdao Runbot Biotechnology Co., Ltd. After the acquisition is completed, Qingdao Runbote Biotechnology Co., Ltd. will become a holding subsidiary of the company, and its financial statements will be included in the company's consolidated financial statements
Qingdao Vland Biotech's Joint Venture to Invest Up to 400 Million Yuan for Probiotic Food Plant
06:00 AM EDT, 03/24/2023 (MT Newswires) -- Aidimeng Weilan Biotechnology (Shandong), a joint venture company of Qingdao Vland Biotech (SHA:603739) with Archer Daniels Midland Singapore, will invest up
Analysis
Price Target
No Data
